TY - JOUR
T1 - Heavy smoking, reduced olanzapine levels, and treatment effects
T2 - A case report
AU - Chiu, Chih Chiang
AU - Lu, Mong Liang
AU - Huang, Ming Chyi
AU - Chen, Kun P.
PY - 2004/10
Y1 - 2004/10
N2 - A 30-year-old schizophrenic male patient, a heavy smoker, was successfully treated with olanzapine 15 mg/d during hospitalization. His cigarette consumption increased rapidly from 12 to 80 cigarettes per day following his discharge. Ten days later, his delusion of persecution, levels of hostility, and aggressive behavior worsened, while the plasma levels of olanzapine concurrently decreased. Based on our observations of this case, we suggest that the reduced levels of plasma olanzapine and exacerbated clinical symptoms are closely related to the increased consumption of cigarettes. A possible explanation would be that heavy smoking induced cytochrome P4501A2, the major enzyme involved in olanzapine metabolism. Therefore, patients who smoke should be closely monitored for their cigarette consumption when the dosage of olanzapine is adjusted.
AB - A 30-year-old schizophrenic male patient, a heavy smoker, was successfully treated with olanzapine 15 mg/d during hospitalization. His cigarette consumption increased rapidly from 12 to 80 cigarettes per day following his discharge. Ten days later, his delusion of persecution, levels of hostility, and aggressive behavior worsened, while the plasma levels of olanzapine concurrently decreased. Based on our observations of this case, we suggest that the reduced levels of plasma olanzapine and exacerbated clinical symptoms are closely related to the increased consumption of cigarettes. A possible explanation would be that heavy smoking induced cytochrome P4501A2, the major enzyme involved in olanzapine metabolism. Therefore, patients who smoke should be closely monitored for their cigarette consumption when the dosage of olanzapine is adjusted.
KW - Cytochrome P450
KW - Olanzapine
KW - Smoking
KW - Therapeutic drug monitoring
UR - http://www.scopus.com/inward/record.url?scp=4744369704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4744369704&partnerID=8YFLogxK
U2 - 10.1097/00007691-200410000-00018
DO - 10.1097/00007691-200410000-00018
M3 - Article
C2 - 15385843
AN - SCOPUS:4744369704
SN - 0163-4356
VL - 26
SP - 579
EP - 581
JO - Therapeutic Drug Monitoring
JF - Therapeutic Drug Monitoring
IS - 5
ER -